The core technology of Chonnam University is the method to produce the recombination fusion protein made by fusing the flagelin of vibrio vulnificus that is the vaccine adjuvant and the toll-similar soluble body-5 (TLR-5) drug with the antigen protein of a pathogenic organism and the vaccine for administration to the mucous membrane including it.
Background and unmet needs
Streptococcus pneumoniae is gram positive diplococcus and is the most important pathogen in the infection of the mucous membrane such as pneumonia glue ear of an infant or an adult and in the invasive infection such as meningitis and bacterimia.
The current vaccine adjuvant is the ectotoxin with high enterotoxicity so that researches are ongoing in the direction to reduce toxicity and enhance adjuvaticity. It was reported in the recent clinical test that administering it with the influenza antigen into the nasal cavity increases the occurrence of Bells's palsy.
The vaccine adjuvant-antigen recombination fusion protein with the improved immunity and the vaccine including it were developed by providing the flagelin having the strong effect of the adjuvant for the mucous membrane vaccine as the vaccine adjuvant and the vaccine adjuvant-antigen recombination fusion protein vaccine for the streptococcus pneumoniae having the surface protein A (PspA) of streptococcus pneumoniae as the antigen.
Discovery and Achievements
The recombination fusion protein produced by fusing the vaccine adjuvant with the antigen in the invention significantly increased the generation of the PspA-specific antigens (IgG and IgA) in the serum and the rheum and also showed the excellent protection immunity to a fatal dose of streptococcus pneumoniae.